Pipeline

Project Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Regulatory Approval
Motixafortide (BL-8040) Stem Cell Mobilization
Pancreatic cancer
AGI-134 Solid tumors

Motixafortide (BL-8040)

Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4, is ...

INDICATIONS : 2

CLINICAL STUDIES : 13

AGI-134

AGI-134 is a synthetic alpha-Gal glycolipid in development for solid tumors that is highly differentiated from other cancer ...

INDICATIONS : 1

CLINICAL STUDIES : 1